The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model
- 360 Downloads
Mesenchymal stem cells (MSCs) have been recognized as promising delivery vehicles for gene therapy of gliomas. The purpose of this study was to evaluate the antitumor effect of cytosine deaminase (CD)-expressing MSCs in a rat C6 glioma model.
Lentiviral vectors expressing cytosine deaminase (CD) or enhanced green fluorescent protein (eGFP) were constructed and transduced into rat MSCs to generate MSC-CD/eGFP cells. By intracranially injecting C6 glioma cells (1 × 106) alone or in combination with parental MSCs (1 × 106 or 2 × 106) or MSC-CD/eGFP cells (1 × 106 or 2 × 106) into rats, we examined the effect of engineered MSCs on tumor growth, tumor cell apoptosis, and rat survival in the presence of 5-fluorocytosine (5-FC).
MSC-CD/eGFP cells were largely localized at the junction of the tumor with normal tissue. The mean survival time of rats co-injected with C6 glioma cells and MSC-CD/eGFP cells was significantly extended (C6 + MSC-CD/eGFP (1:1), 32.3 days; C6 + MSC-CD/eGFP (1:2), 45.9 days) when compared with rats injected with C6 glioma cells alone (15.3 days) or those co-injected with C6 glioma cells and parental cells (C6 + MSCs (1:1), 16.0 days; C6 + MSCs (1:2), 16.6 days). MSC-CD/eGFP-mediated gene therapy significantly reduced the tumor volume in C6 glioma-bearing rats. On day 14 after cell injection, the reduction in the mean tumor volume in rats co-injected with C6 + MSC-CD/eGFP cells (1:1 and 1:2) was 77.24 and 83.28%, respectively. In addition, MSC-CD/eGFP-mediated gene therapy promoted tumor cell apoptosis in rat C6 gliomas.
Genetically engineered MSCs have good therapeutic efficacy against experimental gliomas in rats.
KeywordsGlioma Gene therapy Cytosine deaminase MSCs Lentiviral vector
This work was supported by the Natural Science Foundation of Liaoning Province of China (20092165), Educational Commission of Liaoning Province of China (2008Z081) and Science and Technology Planning Project of Dalian of China (2008E13SF203) and the Fundamental Research Funds for the Central Universities (DUT11SM09).
Conflict of interest
- Amano S, Li S, Gu C et al (2009) Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35(6):1265–1270Google Scholar
- Aoki T (2005) Chemoradiotherapies for malignant gliomas. Nippon Rinsho 63(Suppl 9):472–477Google Scholar
- Davis FG, McCarthy BJ, Berger MS (1999) Centralized databases available for describing primary brain tumor incidence, survival, and treatment: central brain tumor registry of the United States; surveillance, epidemiology, and end results; and national cancer data base. Neuro-Oncol 1(3):205–211PubMedGoogle Scholar
- Huber BE, Austin EA, Richards CA et al (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91:8302–8306PubMedCrossRefGoogle Scholar
- Inada T, Ichikawa A, Kubota T et al (1997) 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res 17(3C):1965–1971Google Scholar
- Lee DH, Ahn Y, Kim SU et al (2009) Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15(15):4925–4934Google Scholar
- Lv SQ, Zhang KB, Zhang EE et al (2009) Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study. Med Sci Monit 15(1):BR13–BR20Google Scholar
- Song F, Xing Q, Ji GC et al (2009) Transfection of mouse bone marrow mesenchymal stem cells with Lipofectamine-mediated cytosine deaminase genes. J Clin Rehab Tissue Eng Res 13(49):9775–9778Google Scholar